Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ropivacaine + epinephrine + ketorolac + clonidine (Atlantic Health System)
- Development stage
- Phase 4
- Lead developer
- Atlantic Health System
- Modality
- Small Molecules
- Administration
- Infiltration, Injection
01
Overview
This is an investigational multidrug cocktail developed by Atlantic Health System for the management of postoperative pain. The combination consists of four active ingredients: ropivacaine, a long-acting amide local anesthetic; epinephrine, a vasoconstrictor that prolongs the duration of the anesthetic; ketorolac, a nonsteroidal anti-inflammatory drug (NSAID) that provides systemic and local analgesia; and clonidine, an alpha-2 adrenergic agonist that enhances the effects of local anesthetics. The cocktail is administered via direct injection into the surgical site to provide multimodal analgesia, aiming to reduce postoperative narcotic consumption. It is currently being evaluated in Phase 2 clinical trials for patients undergoing soft tissue tumor resection.
- Other names
- Multi-Drug Cocktail (Ropivicaine, Epinephrine, Ketolorac, Clonidine)Multidrug Cocktail
02
Targets
ADRA1A (α1A)ADRA2A (α2A)β-AR (Beta-adrenergic receptor family)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HCN (HCN channel family)NaV (Voltage-gated sodium channels)ADRA1 (Alpha-1 adrenergic receptor family)ADRB1 (β1)
Beyond the preview
Go deeper on ropivacaine + epinephrine + ketorolac + clonidine (Atlantic Health System).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ropivacaine + epinephrine + ketorolac + clonidine (Atlantic Health System).